Navigation Links
Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
Date:10/25/2010

PRINCETON, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec® for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.  The preliminary results indicate that orBec® appears safe and well tolerated in this patient population, but did not achieve statistical significance in the primary endpoint, which was the proportion of subjects who developed acute GVHD with severity sufficient to require systemic immunosuppressive treatment on or before day 90 after transplantation.  However, an encouraging result was that use of orBec® resulted in fewer cases of more severe acute GVHD grades IIb-IV (21% vs. 33% of patients receiving placebo), although this difference was not statistically significant.  This result has the potential to be clinically relevant because GVHD grades IIb-IV are associated with more severe disease involving the skin and liver as well as being associated with poorer outcomes, including mortality rates that approach 100% in the grade IV patient population.  Further analysis of the complete dataset continues and is aimed at identifying other potential effects seen with orBec® in preventing acute GVHD.

The Phase 2 prevention study was a randomized, double-blind, placebo-controlled trial that enrolled 140 patients who had been randomized to either orBec® or placebo at a 2:1 ratio.  Prior to HCT, patients began study drug at the start of their conditioning regimen and continued through day 75 following HCT. The study was con
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... being recalled after Health Canada tests confirmed it contains ... risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution ... the product from retail stores across Canada ... purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... Kinex Pharmaceuticals announced today that the first ... Cancer Institute. KX2-361 (KX02), a dual src/pre-tubulin ... potent inhibitory activity against a broad panel of brain ... Temozolomide (T98G), the most widely used chemotherapy for the ... mouse model, KX2-361 consistently clears brain tumors after 4 ...
(Date:12/24/2014)... N.J. and FARMINGTON, Conn. ... Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company ... of diseases with significant unmet medical need and ... on a private placement of 2,050,000 shares of ... purchase 24,949,325 shares of its common stock.  Funds ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... Calif., April 7, 2011 MEDomics, LLC provides ... medicine in the genomics era and is transforming ... to announce a growth capital investment from our ... from SpaGus will be used by MEDomics to ...
... Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president ... CHI conferences.  Dr. Fernandes will present at the ... 5 p.m. PDT, April 12, at the Hilton San ... "Macrolides as a New Class of Orally Active Anti-Inflammatory ...
Cached Medicine Technology:MEDomics Announces a Growth Capital Investment from SpaGus Ventures LLC and Gary Augusta Joins MEDomics as Chief Operating Officer 2Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences 2
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... The click strand woven ... and durability. Today, the business announces a click ... until Jan. 30, 2015. , Click strand woven ... BambooFlooringChina.com is a well-known brand in the bamboo ... find a reliable bamboo flooring supplier. , “We ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... anti-cancer drug which is typically used for treating colorectal ... for treating gastric cancer and pancreatic cancer. TS-1 is ... was first approved in 1999 in Japan for the ...
(Date:12/25/2014)... December 26, 2014 “Every three months the ... changes. A-line sweetheart evening dress will be one of the ... manager of Yunx.co.uk says. Today, the company releases 26 A-line ... up to 80% off. , “We are trying our ... style with our latest designs. Along with affordable prices, we ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... July 16 (IANS) Five patients have died amid a strike ... (PMCH), which entered its third day Saturday crippling medical services. ... sources said. Hundreds of patients, mostly poor people who have ... ,"We are the real victims of the strike because ...
... the biggest cancer killers in industrial countries and affects ... is expected to increase with the ageing population, prompting ... daily supplement containing plant oestrogens and antioxidants like selenium ... a marker for prostate cancer progression in some men. ...
... mutation in gene ENPP1 may contribute to obesity and ... from the Institute of Pasteur in Lille, France, collaborated ... Britain recruited obese children aged between 5 and 11 ... children’s from 1,225 obese children and 1,205 normal weighed ...
... mainly farm animals and spread in humans// by inhaling spores from ... not taken. Now a report of Anthrax among the farm animals ... this disease among the health officials. ,Kerala has also imposed ... Pollachi – a market town on the border of Kerala and ...
... a cluster of genetic mutations accelerate the series of ... the researchers from the University of Wisconsin-Madison, growing old ... the mitochondria triggers cell deaths that may lead to ... weakening of the bone structures and less number of ...
... for the International Society for Biomedical Research// on Alcoholism ... alcohol abuse and cure had said that early detection ... any other forms of treatment. ,Researchers suggest that ... and detailed questionnaires to predict the alcohol addiction ...
Cached Medicine News:Health News:Tackling Prostate Cancer With A New Dietary Supplement 2Health News:Anthrax Scare In Tamil Nadu State of India 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: